Close Menu
    Trending
    Health

    UniQure, Moderna, Eli Lilly, Huntington’s: Readout Newsletter

    Al Punto Hoy from ANASTACIO ALEGRIABy No hay comentarios5 Views
    UniQure, Moderna, Eli Lilly, Huntington’s: Readout Newsletter


    Adobe

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

    Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on Signal at hbranswell.01.

    Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

    Good morning. Today, one venture capitalist weighs in on the China biotech debate. Let me know if you agree with her or not.

    UniQure will submit Huntington’s therapy for approval

    The FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval, the company said morning.

    STAT+ Exclusive Story

    Eli Lilly retatrutide, Khartis, Neurocrine, insulin: Readout Newsletter





    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. National Biotech Reporter

      The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

    2. Infectious Diseases Correspondent

      Mastodon and Bluesky. You can reach Helen on Signal at hbranswell.01.

    Share.

    Related Posts

    Leave A Reply